Cases
PixarBio Corporation fka BMP Holdings, Inc. (OTC BB: PXRB)
Securities Class Action
Overview
Overview
- Date:
- 1/25/2017
- Company Name:
- PixarBio Corporation
- Stock Symbol:
- PXRB
- Class Period:
- FROM 10/10/2016 TO 1/20/2017
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Central California
NEW YORK, January 25, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who acquired PixarBio Corporation f/k/a BMP Holdings, Inc. (OTC BB: PXRB) securities between August 2, 2016 and November 16, 2016 (the “Class Period”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders, the identity and qualifications of key shareholders and employees, and PixarBio’s current and prospective development efforts lacked veracity. As of the foregoing, Defendants’ public statements were materially false and misleading throughout the Class Period.
On October 30, 2016, PixarBio completed its merger transaction with BMP Holdings, a division of the Company, and executed a 10:1 stock split effective October 31, 2016.
On January 23, 2017, the U.S. Securities and Exchange Commission (the “SEC”) halted trading in the securities of PixarBio, citing concerns about possible “manipulative or deceptive activities” in the market for the Company’s stock.
If you purchased or otherwise acquired PixarBio common stock during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) PixarBio’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders, the identity and qualifications of key shareholders and employees, and PixarBio’s current and prospective development efforts lacked veracity. As of the foregoing, Defendants’ public statements were materially false and misleading throughout the Class Period.
On October 30, 2016, PixarBio completed its merger transaction with BMP Holdings, a division of the Company, and executed a 10:1 stock split effective October 31, 2016.
On January 23, 2017, the U.S. Securities and Exchange Commission (the “SEC”) halted trading in the securities of PixarBio, citing concerns about possible “manipulative or deceptive activities” in the market for the Company’s stock.
If you purchased or otherwise acquired PixarBio common stock during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.